Mometasonfuroat Cipla (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors inside nasal epithelial cells. The drug‑receptor complex moves to the cell nucleus and alters gene transcription, suppressing the production of inflammatory cytokines, chemokines and mediators such as prostaglandins and leukotrienes, which results in reduced nasal inflammation.

The appropriate dose of Mometasonfuroat Cipla is set by the prescribing healthcare professional based on the patient’s age, severity of symptoms and clinical response. Dosage recommendations are provided in the product labeling, and patients should follow the prescriber’s instructions without deviation.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their physician before using the product.

To place an enquiry, visit the product page on gnhindia.com and submit the required quantity details. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping options and any necessary import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with agents such as fluticasone or budesonide, it offers similar efficacy in symptom control but may have a lower systemic absorption, reducing the risk of systemic side effects.

Store the nasal spray at room temperature, preferably below 25 °C (77 °F). Keep the container tightly closed, protect it from moisture and direct sunlight, and retain it in the original packaging until use. Do not freeze the product.

The spray is intended for intranasal use only. The patient should gently blow the nose, insert the nozzle into each nostril, and spray the prescribed number of actuations while inhaling gently. The recommended technique and number of sprays per day are provided by the prescriber.

Serious adverse events, although rare, include nasal septal perforation, cataract or glaucoma formation with prolonged therapy, and suppression of the hypothalamic‑pituitary‑adrenal axis leading to systemic glucocorticoid effects. Patients should report persistent visual changes, severe nosebleeds or signs of adrenal insufficiency to a healthcare professional promptly.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with active untreated fungal, viral or bacterial infections of the nasal passages until the infection has been resolved.